
    
      PA32540 is proposed for the secondary prevention of cardio- and cerebrovascular events in
      patients at risk for developing aspirin-associated gastric ulcers. This study is designed to
      provide long-term safety data for PA32540 in order to gain regulatory approval to make
      PA32540 available for clinical use in this subject population.
    
  